Elevated serum levels of interleukin-37 correlate with poor prognosis in gastric cancer

ABSTRACT

Background: interleukin-37 (IL-37) is as a natural suppressor of the innate inflammatory and immune responses. It has also been reported to be involved in carcinogenesis and metastasis. The present case-control study was designed to investigate the role of serum levels of IL-37 in patients with gastric cancer. Methods: serum IL-37 levels were determined using the enzyme-linked immunosorbent assay in 180 patients diagnosed with gastric cancer and 100 healthy controls. The association between IL-37 levels and clinical factors was assessed. Univariate and multivariate analyses were performed to investigate the prognostic significance of these parameters in gastric cancer. Results: serum IL-37 levels in gastric cancer patients (5.606 +/- 0.837 pg/ml) were significantly higher than those in healthy controls (2.364 +/- 0.210 pg/ml, p < 0.001). High serum IL-37 levels were related to a poorly differentiated histologic type (p = 0.046) and advanced T stage (p = 0.003). The Kaplan-Meier survival analysis indicated that the high-IL-37 group had a poorer overall survival and progression-free survival (overall survival [OS] 39.0 months vs 13.0 months, p < 0.001, progression-free survival [PFS] 25.0 months vs 10.0 months, p < 0.001). Multivariate analyses showed serum IL-37 to be an independent prognostic factor for gastric cancer patients (OS hazard ratios [HR] = 1.842, 95% CI 1.190-2.854, p = 0.006; PFS HR = 1.547, 95% CI 1.014-2.359, p = 0.043). Conclusions: in conclusion, serum IL-37 levels were associated with poor overall survival and progression-free survival in gastric cancer patients. IL-37 may be a potential predictor of prognosis in gastric cancer

RESUMEN

No disponible